Loading...

HRTX HERON THERAPEUTICS INC Management Changes 8-K Filing

HRN

HRTX

HERON THERAPEUTICS INC

(HRTX)

2025 8-K

Show Summary

Show Summary

Financial Statements

Regulatory Compliance

Earnings Results

Loan Agreement Amendment

Headquarters Relocation

Patent Litigation Win

Earnings Announcement

Board Appointment

Earnings Release

FDA Acknowledgment of ZYNRE...

Annual Meeting Approval

Earnings Release

Earnings Release

FDA Approval for ZYNRELEF

Co-Promotion Agreement

Notice of Generic Version

Resignation of Director

Earnings Release

Earnings Release

Equity Offerings

Appointment of CFO

Management Changes

Financial Results Announcement

Departure of Directors and ...

Appointment of CEO and Chai...

External Links:

On April 28, 2025, Heron Therapeutics, Inc. appointed Mark Hensley as Chief Operating Officer, effective the same day, with a base salary of $553,000 and a target bonus of $276,500. He also received significant stock options and restricted stock unit

AI Assistant

HERON THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.